Why the study?
Does low dose aripiprazole improve psychotic symptoms in a patient with Kufor-Rakeb syndrome?
Does low dose aripiprazole improve psychotic symptoms in a patient with Kufor-Rakeb syndrome?
Low dose aripiprazole (2-3 mg) may be effective and well-tolerated for treating psychosis in patients with Kufor-Rakeb syndrome without exacerbating motor symptoms.
May offer motor-sparing option for psychosis in Kufor-Rakeb syndrome; leaves open confirmation in controlled trials.
We present a case of a 32-year-old male with Kufor-Rakeb syndrome (KRS), a form of juvenile parkinsonism due to mutations of the ATP13A2 gene at PARK9 locus. The patient was seen for daily behavioral outbursts and psychotic symptoms. At first assessment, CGI scale was estimated at 5; "Markedly ill". Aripiprazole was started at 2 mg and then increased to 3 mg. Two years later, psychotic symptoms were judged to be "much improved" (CGI-C = 2). This significant improvement without drug-induced motor side effects suggests that aripiprazole at low doses (2-5 mg) is effective and tolerated in patients with KRS.
No takes yet. Share an insight, caveat, or question.
McNeil-Gauthier et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: